View in EDS

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Saved in:
Bibliographic Details
Title: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
Authors: van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands., Pipinikas C; Inivata Ltd., Babraham Research Park, Cambridge, UK., Suelmann BBM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Dijk N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marsico G; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Montfoort ML; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hackinger S; Inivata Ltd., Babraham Research Park, Cambridge, UK., Braaf LM; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., McLay K; Inivata Ltd., Babraham Research Park, Cambridge, UK., Daletzakis A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer RP; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Rosenfeld N; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK., van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Jones G; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com., van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.
Source: Nature medicine [Nat Med] 2023 Mar; Vol. 29 (3), pp. 588-592. Date of Electronic Publication: 2023 Feb 02.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36732628
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22van+Dorp+J%22">van Dorp J</searchLink>; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pipinikas+C%22">Pipinikas C</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Suelmann+BBM%22">Suelmann BBM</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mehra+N%22">Mehra N</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Dijk+N%22">van Dijk N</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Marsico+G%22">Marsico G</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Montfoort+ML%22">van Montfoort ML</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hackinger+S%22">Hackinger S</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Braaf+LM%22">Braaf LM</searchLink>; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Amarante+T%22">Amarante T</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Steenis+C%22">van Steenis C</searchLink>; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22McLay+K%22">McLay K</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Daletzakis+A%22">Daletzakis A</searchLink>; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Broek+D%22">van den Broek D</searchLink>; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+de+Kamp+MW%22">van de Kamp MW</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hendricksen+K%22">Hendricksen K</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Feijter+JM%22">de Feijter JM</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Boellaard+TN%22">Boellaard TN</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meijer+RP%22">Meijer RP</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+AG%22">van der Heijden AG</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Rosenfeld+N%22">Rosenfeld N</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Rhijn+BWG%22">van Rhijn BWG</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Jones+G%22">Jones G</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+MS%22">van der Heijden MS</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2023 Mar; Vol. 29 (3), pp. 588-592. <i>Date of Electronic Publication: </i>2023 Feb 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36732628
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-022-02199-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 588
    Titles:
      – TitleFull: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: van Dorp J
      – PersonEntity:
          Name:
            NameFull: Pipinikas C
      – PersonEntity:
          Name:
            NameFull: Suelmann BBM
      – PersonEntity:
          Name:
            NameFull: Mehra N
      – PersonEntity:
          Name:
            NameFull: van Dijk N
      – PersonEntity:
          Name:
            NameFull: Marsico G
      – PersonEntity:
          Name:
            NameFull: van Montfoort ML
      – PersonEntity:
          Name:
            NameFull: Hackinger S
      – PersonEntity:
          Name:
            NameFull: Braaf LM
      – PersonEntity:
          Name:
            NameFull: Amarante T
      – PersonEntity:
          Name:
            NameFull: van Steenis C
      – PersonEntity:
          Name:
            NameFull: McLay K
      – PersonEntity:
          Name:
            NameFull: Daletzakis A
      – PersonEntity:
          Name:
            NameFull: van den Broek D
      – PersonEntity:
          Name:
            NameFull: van de Kamp MW
      – PersonEntity:
          Name:
            NameFull: Hendricksen K
      – PersonEntity:
          Name:
            NameFull: de Feijter JM
      – PersonEntity:
          Name:
            NameFull: Boellaard TN
      – PersonEntity:
          Name:
            NameFull: Meijer RP
      – PersonEntity:
          Name:
            NameFull: van der Heijden AG
      – PersonEntity:
          Name:
            NameFull: Rosenfeld N
      – PersonEntity:
          Name:
            NameFull: van Rhijn BWG
      – PersonEntity:
          Name:
            NameFull: Jones G
      – PersonEntity:
          Name:
            NameFull: van der Heijden MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2023 Mar
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1